Mealey's Antitrust/Unfair Competition - Untimely Claims In Investor Suit Against Drug Maker, Others Dismissed

TRENTON, N.J. - A federal judge in New Jersey on Sept. 10 ruled that dismissal of a securities class action lawsuit against specialty pharmaceutical and medical device company Valeant Pharmaceuticals International Inc. and certain of its former senior executives is necessary because the shareholders' claims are untimely and not subject to tolling pursuant to the American Pipe & Construction Co. v. Utah tolling doctrine (Bahaa Aly, et al. v. Valeant Pharmaceuticals International Inc., et al., No. 18-17393, D. N.J., 2019 U.S. Dist. LEXIS 155223).
Find full version on lexis Advance®